Host effects contributing to cancer therapy resistance

Drug Resistance Updates

Volumn 19, Issue , 2015, Pages 33-42

  Katz, Ofrat Beyar ^a   Shaked, Yuval ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Bone marrow derived cells; Chemotherapy; Cytokines; Radiation

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL; DRUG DESIGN; DRUG RESISTANCE; HUMAN; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84939986130     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2014.12.002     Document Type: Article

References (90)

1. G.O. Ahn, and J.M. Brown Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells Cancer Cell 13 3 2008 193 205
2. D. Alishekevitz, R. Bril, D. Loven, V. Miller, T. Voloshin, S. Gingis-Velistki, E. Fremder, S.J. Scherer, and Y. Shaked Differential therapeutic effects of anti-VEGF-A antibody in different tumor models: implications for choosing appropriate tumor models for drug testing Mol. Cancer Ther. 13 1 2014 202 213
3. T. Asahara, T. Takahashi, H. Masuda, C. Kalka, D. Chen, H. Iwaguro, Y. Inai, M. Silver, and J.M. Isner VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells EMBO J. 18 14 1999 3964 3972
4. Y.G. Assaraf, C.P. Leamon, and J.A. Reddy The folate receptor as a rational therapeutic target for personalized cancer treatment Drug Resist. Updat. 17 4-6 2014 89 95
5. B.M. Beckermann, G. Kallifatidis, A. Groth, D. Frommhold, A. Apel, J. Mattern, A.V. Salnikov, G. Moldenhauer, W. Wagner, A. Diehlmann, R. Saffrich, M. Schubert, A.D. Ho, N. Giese, M.W. Buchler, H. Friess, P. Buchler, and I. Herr VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma Br. J. Cancer 99 4 2008 622 631
6. L.V. Beerepoot, S.A. Radema, E.O. Witteveen, T. Thomas, C. Wheeler, S. Kempin, and E.E. Voest Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors J. Clin. Oncol. 24 10 2006 1491 1498
7. N.A. Bhowmick, E.G. Neilson, and H.L. Moses Stromal fibroblasts in cancer initiation and progression Nature 432 7015 2004 332 337
8. G. Bocci, S. Man, S.K. Green, G. Francia, J.M. Ebos, J.M. Du Manoir, A. Weinerman, U. Emmenegger, L. Ma, P. Thorpe, A. Davidoff, J. Huber, D.J. Hicklin, and R.S. Kerbel Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies Cancer Res. 64 18 2004 6616 6625
9. M. Bruchard, G. Mignot, V. Derangere, F. Chalmin, A. Chevriaux, F. Vegran, W. Boireau, B. Simon, B. Ryffel, J.L. Connat, J. Kanellopoulos, F. Martin, C. Rebe, L. Apetoh, and F. Ghiringhelli Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth Nat. Med. 19 1 2013 57 64
10. Y. Carmi, S. Dotan, P. Rider, I. Kaplanov, M.R. White, R. Baron, S. Abutbul, M. Huszar, C.A. Dinarello, R.N. Apte, and E. Voronov The role of IL-1beta in the early tumor cell-induced angiogenic response J. Immunol. 190 7 2013 3500 3509
11. O. Casanovas, D.J. Hicklin, G. Bergers, and D. Hanahan Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors Cancer Cell 8 4 2005 299 309
12. F. Cavallo, C. De Giovanni, P. Nanni, G. Forni, and P.L. Lollini 2011: the immune hallmarks of cancer Cancer Immunol. Immunother. 60 3 2011 319 326
13. S.B. Coffelt, A.O. Tal, A. Scholz, M. De Palma, S. Patel, C. Urbich, S.K. Biswas, C. Murdoch, K.H. Plate, Y. Reiss, and C.E. Lewis Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions Cancer Res. 70 13 2010 5270 5280
14. L.M. Coussens, B. Fingleton, and L.M. Matrisian Matrix metalloproteinase inhibitors and cancer: trials and tribulations Science 295 5564 2002 2387 2392
15. L.G. Daenen, J.M. Roodhart, M. Van Amersfoort, M. Dehnad, W. Roessingh, L.H. Ulfman, P.W. Derksen, and E.E. Voest Chemotherapy enhances metastasis formation via VEGFR-1-expressing endothelial cells Cancer Res. 71 22 2011 6976 6985
16. M. De Palma, and C.E. Lewis Macrophage regulation of tumor responses to anticancer therapies Cancer Cell 23 3 2013 277 286
17. D.G. DeNardo, D.J. Brennan, E. Rexhepaj, B. Ruffell, S.L. Shiao, S.F. Madden, W.M. Gallagher, N. Wadhwani, S.D. Keil, S.A. Junaid, H.S. Rugo, E.S. Hwang, K. Jirstrom, B.L. West, and L.M. Coussens Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy Cancer Discov. 1 1 2011 54 67
18. J.M. Ebos, C.R. Lee, J.G. Christensen, A.J. Mutsaers, and R.S. Kerbel Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy Proc. Natl. Acad. Sci. U. S. A. 104 43 2007 17069 17074
19. J.M. Ebos, C.R. Lee, W. Cruz-Munoz, G.A. Bjarnason, J.G. Christensen, and R.S. Kerbel Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis Cancer Cell 15 3 2009 232 239
20. S.Y. El Sharouni, H.B. Kal, and J.J. Battermann Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy Br. J. Cancer 89 12 2003 2184 2189
21. L.M. Ellis, and D.J. Hicklin VEGF-targeted therapy: mechanisms of anti-tumour activity Nat. Rev. Cancer 8 8 2008 579 591
22. U. Emmenegger, G. Francia, A. Chow, Y. Shaked, A. Kouri, S. Man, and R.S. Kerbel Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide Neoplasia 13 1 2011 40 48
23. F. Farace, C. Massard, E. Borghi, J.M. Bidart, and J.C. Soria Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor cells Ann. Oncol. 18 8 2007 1421 1422
24. J. Folkman Angiogenesis and apoptosis Semin. Cancer Biol. 13 2 2003 159 167
25. D. Gao, D.J. Nolan, A.S. Mellick, K. Bambino, K. Mcdonnell, and V. Mittal Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis Science 319 5860 2008 195 198
26. L.A. Gilbert, and M.T. Hemann DNA damage-mediated induction of a chemoresistant niche Cell 143 3 2010 355 366
27. S. Gingis-Velitski, D. Loven, L. Benayoun, M. Munster, R. Bril, T. Voloshin, D. Alishekevitz, F. Bertolini, and Y. Shaked Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice Cancer Res. 71 22 2011 6986 6996
28. V. Gocheva, H.W. Wang, B.B. Gadea, T. Shree, K.E. Hunter, A.L. Garfall, T. Berman, and J.A. Joyce IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion Genes Dev. 24 3 2010 241 255
29. N. Gonen, and Y.G. Assaraf Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance Drug Resist. Updat. 15 4 2012 183 210
30. M.M. Gottesman, T. Fojo, and S.E. Bates Multidrug resistance in cancer: role of ATP-dependent transporters Nat. Rev. Cancer 2 1 2002 48 58
31. M. Grunewald, I. Avraham, Y. Dor, E. Bachar-Lustig, A. Itin, S. Jung, S. Chimenti, L. Landsman, R. Abramovitch, and E. Keshet VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells Cell 124 1 2006 175 189
32. D. Hanahan, and L.M. Coussens Accessories to the crime: functions of cells recruited to the tumor microenvironment Cancer Cell 21 3 2012 309 322
33. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 5 2011 646 674
34. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 1 2000 57 70
35. E. Hasnis, D. Alishekevitz, S. Gingis-Veltski, R. Bril, E. Fremder, T. Voloshin, Z. Raviv, A. Karban, and Y. Shaked Anti-Bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy Neoplasia 16 2014 501 510
36. K. Hattori, S. Dias, B. Heissig, N.R. Hackett, D. Lyden, M. Tateno, D.J. Hicklin, Z. Zhu, L. Witte, R.G. Crystal, M.A. Moore, and S. Rafii Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells J. Exp. Med. 193 9 2001 1005 1014
37. B. Heissig, S. Rafii, H. Akiyama, Y. Ohki, Y. Sato, T. Rafael, Z. Zhu, D.J. Hicklin, K. Okumura, H. Ogawa, Z. Werb, and K. Hattori Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9-mediated progenitor cell mobilization J. Exp. Med. 202 6 2005 739 750
38. C.F. Higgins ABC transporters: from microorganisms to man Annu. Rev. Cell Biol. 8 1992 67 113
39. C. Holohan, S. Van Schaeybroeck, D.B. Longley, and P.G. Johnston Cancer drug resistance: an evolving paradigm Nat. Rev. Cancer 13 10 2013 714 726
40. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross, and F. Kabbinavar Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N. Engl. J. Med. 350 23 2004 2335 2342
41. A. Kaliski, L. Maggiorella, K.A. Cengel, D. Mathe, V. Rouffiac, P. Opolon, N. Lassau, J. Bourhis, and E. Deutsch Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion Mol. Cancer Ther. 4 11 2005 1717 1728
42. A.E. Karnoub, A.B. Dash, A.P. Vo, A. Sullivan, M.W. Brooks, G.W. Bell, A.L. Richardson, K. Polyak, R. Tubo, and R.A. Weinberg Mesenchymal stem cells within tumour stroma promote breast cancer metastasis Nature 449 7162 2007 557 563
43. J.J. Kim, and I.F. Tannock Repopulation of cancer cells during therapy: an important cause of treatment failure Nat. Rev. Cancer 5 7 2005 516 525
44. S.J. Kim, J.S. Kim, E.S. Park, J.S. Lee, Q. Lin, R.R. Langley, M. Maya, J. He, S.W. Kim, Z. Weihua, K. Balasubramanian, D. Fan, G.B. Mills, M.C. Hung, and I.J. Fidler Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy Neoplasia 13 3 2011 286 298
45. M. Kioi, H. Vogel, G. Schultz, R.M. Hoffman, G.R. Harsh, and J.M. Brown Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice J. Clin. Invest. 120 3 2010 694 705
46. J.C. Kovacic, and M. Boehm Resident vascular progenitor cells: an emerging role for non-terminally differentiated vessel-resident cells in vascular biology Stem Cell Res. 2 1 2009 2 15
47. S.V. Kozin, W.S. Kamoun, Y. Huang, M.R. Dawson, R.K. Jain, and D.G. Duda Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation Cancer Res. 70 14 2010 5679 5685
48. R. Krishna, and L.D. Mayer Multidrug resistance (MDR) in cancer, mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs Eur. J. Pharm. Sci. 11 4 2000 265 283
49. C. Lamagna, and G. Bergers The bone marrow constitutes a reservoir of pericyte progenitors J. Leukoc. Biol. 80 4 2006 677 681
50. K.S. Lee, H.C. Chung, S.A. Im, Y.H. Park, C.S. Kim, S.B. Kim, S.Y. Rha, M.Y. Lee, and J. Ro Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer Breast Cancer Res. Treat. 108 2 2008 241 250
51. C.E. Lewis, and J.W. Pollard Distinct role of macrophages in different tumor microenvironments Cancer Res. 66 2 2006 605 612
52. B.C. Liang, A.F. Thornton Jr.; H.M. Sandler, and H.S. Greenberg Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy J. Neurosurg. 75 4 1991 559 563
53. Y.D. Livney, and Y.G. Assaraf Rationally designed nanovehicles to overcome cancer chemoresistance Adv. Drug Deliv. Rev. 65 13-14 2013 1716 1730
54. Y. Ma, S. Adjemian, S.R. Mattarollo, T. Yamazaki, L. Aymeric, H. Yang, J.P. Portela Catani, D. Hannani, H. Duret, K. Steegh, I. Martins, F. Schlemmer, M. Michaud, O. Kepp, A.Q. Sukkurwala, L. Menger, E. Vacchelli, N. Droin, L. Galluzzi, R. Krzysiek, S. Gordon, P.R. Taylor, P. Van Endert, E. Solary, M.J. Smyth, L. Zitvogel, and G. Kroemer Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells Immunity 38 4 2013 729 741
55. D. Miles, N. Harbeck, B. Escudier, H. Hurwitz, L. Saltz, E. Van Cutsem, J. Cassidy, B. Mueller, and F. Sirzen Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials J. Clin. Oncol. 29 1 2011 83 88
56. M. Morigi, M. Introna, B. Imberti, D. Corna, M. Abbate, C. Rota, D. Rottoli, A. Benigni, N. Perico, C. Zoja, A. Rambaldi, A. Remuzzi, and G. Remuzzi Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice Stem Cells 26 8 2008 2075 2082
57. J. Nemunaitis, C. Cunningham, N. Senzer, M. Gray, F. Oldham, J. Pippen, R. Mennel, and A. Eisenfeld Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors Cancer Invest. 23 8 2005 671 676
58. D.H. Nguyen, H.A. Oketch-Rabah, I. Illa-Bochaca, F.C. Geyer, J.S. Reis-Filho, J.H. Mao, S.A. Ravani, J. Zavadil, A.D. Borowsky, D.J. Jerry, K.A. Dunphy, J.H. Seo, S. Haslam, D. Medina, and M.H. Barcellos-Hoff Radiation acts on the microenvironment to affect breast carcinogenesis by distinct mechanisms that decrease cancer latency and affect tumor type Cancer Cell 19 5 2011 640 651
59. P.G. Nikolinakos, N. Altorki, D. Yankelevitz, H.T. Tran, S. Yan, D. Rajagopalan, W. Bordogna, L.H. Ottesen, and J.V. Heymach Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib Cancer Res. 70 6 2010 2171 2179
60. A. Norden-Zfoni, J. Desai, J. Manola, P. Beaudry, J. Force, R. Maki, J. Folkman, C. Bello, C. Baum, S.E. Deprimo, D.R. Shalinsky, G.D. Demetri, and J.V. Heymach Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor Clin. Cancer Res. 13 9 2007 2643 2650
61. M. Paez-Ribes, E. Allen, J. Hudock, T. Takeda, H. Okuyama, F. Vinals, M. Inoue, G. Bergers, D. Hanahan, and O. Casanovas Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 15 3 2009 220 231
62. A. Patenaude, J. Parker, and A. Karsan Involvement of endothelial progenitor cells in tumor vascularization Microvasc. Res. 79 3 2010 217 223
63. Y. Patil, and J. Panyam Polymeric nanoparticles for siRNA delivery and gene silencing Int. J. Pharm. 367 1-2 2009 195 203
64. T.J. Perren, A.M. Swart, J. Pfisterer, J.A. Ledermann, E. Pujade-Lauraine, G. Kristensen, M.S. Carey, P. Beale, A. Cervantes, C. Kurzeder, A. Du Bois, J. Sehouli, R. Kimmig, A. Stahle, F. Collinson, S. Essapen, C. Gourley, A. Lortholary, F. Selle, M.R. Mirza, A. Leminen, M. Plante, D. Stark, W. Qian, M.K. Parmar, A.M. Oza Icon7 Investigators A phase 3 trial of bevacizumab in ovarian cancer N. Engl. J. Med. 365 26 2011 2484 2496
65. K. Pietras, and D. Hanahan A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer J. Clin. Oncol. 23 5 2005 939 952
66. J.M. Roodhart, L.G. Daenen, E.C. Stigter, H.J. Prins, J. Gerrits, J.M. Houthuijzen, M.G. Gerritsen, H.S. Schipper, M.J. Backer, M. Van Amersfoort, J.S. Vermaat, P. Moerer, K. Ishihara, E. Kalkhoven, J.H. Beijnen, P.W. Derksen, R.H. Medema, A.C. Martens, A.B. Brenkman, and E.E. Voest Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids Cancer Cell 20 3 2011 370 383
67. J.M. Roodhart, M.H. Langenberg, J.S. Vermaat, M.P. Lolkema, A. Baars, R.H. Giles, E.O. Witteveen, and E.E. Voest Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients Neoplasia 12 1 2010 87 94
68. A. Sandler, R. Gray, M.C. Perry, J. Brahmer, J.H. Schiller, A. Dowlati, R. Lilenbaum, and D.H. Johnson Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N. Engl. J. Med. 355 24 2006 2542 2550
69. R. Scherz-Shouval, S. Santagata, M.L. Mendillo, L.M. Sholl, I. Ben-Aharon, A.H. Beck, D. Dias-Santagata, M. Koeva, S.M. Stemmer, L. Whitesell, and S. Lindquist The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy Cell 158 3 2014 564 578
70. T. Sethi, R.C. Rintoul, S.M. Moore, A.C. Mackinnon, D. Salter, C. Choo, E.R. Chilvers, I. Dransfield, S.C. Donnelly, R. Strieter, and C. Haslett Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo Nat. Med. 5 6 1999 662 668
71. Y. Shaked, A. Ciarrocchi, M. Franco, C.R. Lee, S. Man, A.M. Cheung, D.J. Hicklin, D. Chaplin, F.S. Foster, R. Benezra, and R.S. Kerbel Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors Science 313 5794 2006 1785 1787
72. Y. Shaked, U. Emmenegger, G. Francia, L. Chen, C.R. Lee, S. Man, A. Paraghamian, Y. Ben-David, and R.S. Kerbel Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy Cancer Res. 65 16 2005 7045 7051
73. Y. Shaked, E. Henke, J.M. Roodhart, P. Mancuso, M.H. Langenberg, M. Colleoni, L.G. Daenen, S. Man, P. Xu, U. Emmenegger, T. Tang, Z. Zhu, L. Witte, R.M. Strieter, F. Bertolini, E.E. Voest, R. Benezra, and R.S. Kerbel Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents Cancer Cell 14 3 2008 263 273
74. Y. Shaked, and R.S. Kerbel Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy Cancer Res. 67 15 2007 7055 7058
75. Y. Shaked, T. Tang, J. Woloszynek, L.G. Daenen, S. Man, P. Xu, S.R. Cai, J.M. Arbeit, E.E. Voest, D.J. Chaplin, J. Smythe, A. Harris, P. Nathan, I. Judson, G. Rustin, F. Bertolini, D.C. Link, and R.S. Kerbel Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents Cancer Res. 69 19 2009 7524 7528
76. M.P. Shekhar, S. Santner, K.A. Carolin, and L. Tait Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity Am. J. Pathol. 170 5 2007 1546 1560
77. F. Shojaei, and N. Ferrara Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells Cancer Res. 68 14 2008 5501 5504
78. F. Shojaei, X. Wu, A.K. Malik, C. Zhong, M.E. Baldwin, S. Schanz, G. Fuh, H.P. Gerber, and N. Ferrara Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells Nat. Biotechnol. 25 8 2007 911 920
79. T. Shree, O.C. Olson, B.T. Elie, J.C. Kester, A.L. Garfall, K. Simpson, K.M. Bell-Mcguinn, E.C. Zabor, E. Brogi, and J.A. Joyce Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer Genes Dev. 25 23 2011 2465 2479
80. M.R. Shurin Dual role of immunomodulation by anticancer chemotherapy Nat. Med. 19 1 2013 20 22
81. A. Sica, T. Schioppa, A. Mantovani, and P. Allavena Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy Eur. J. Cancer 42 6 2006 717 727
82. I. Sofia Vala, L.R. Martins, N. Imaizumi, R.J. Nunes, J. Rino, F. Kuonen, L.M. Carvalho, C. Ruegg, I.M. Grillo, J.T. Barata, M. Mareel, and S.C. Santos Low doses of ionizing radiation promote tumor growth and metastasis by enhancing angiogenesis PLoS ONE 5 6 2010 e11222
83. X. Song, Y. Krelin, T. Dvorkin, O. Bjorkdahl, S. Segal, C.A. Dinarello, E. Voronov, and R.N. Apte CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells J. Immunol. 175 12 2005 8200 8208
84. R. Straussman, T. Morikawa, K. Shee, M. Barzily-Rokni, Z.R. Qian, J. Du, A. Davis, M.M. Mongare, J. Gould, D.T. Frederick, Z.A. Cooper, P.B. Chapman, D.B. Solit, A. Ribas, R.S. Lo, K.T. Flaherty, S. Ogino, J.A. Wargo, and T.R. Golub Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion Nature 487 7408 2012 500 504
85. Y. Sun, J. Campisi, C. Higano, T.M. Beer, P. Porter, I. Coleman, L. True, and P.S. Nelson Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B Nat. Med. 18 9 2012 1359 1368
86. T. Voloshin, S. Gingis-Velitski, R. Bril, L. Benayoun, M. Munster, C. Milsom, S. Man, R.S. Kerbel, and Y. Shaked G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist Blood 118 12 2011 3426 3435
87. E. Voronov, Y. Carmi, and R.N. Apte The role IL-1 in tumor-mediated angiogenesis Front. Physiol. 5 2014 114
88. A.F. Welford, D. Biziato, S.B. Coffelt, S. Nucera, M. Fisher, F. Pucci, C. Di Serio, L. Naldini, M. De Palma, G.M. Tozer, and C.E. Lewis TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice J. Clin. Invest. 121 5 2011 1969 1973
89. J. Xu, J. Escamilla, S. Mok, J. David, S. Priceman, B. West, G. Bollag, W. Mcbride, and L. Wu CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer Cancer Res. 73 9 2013 2782 2794
90. W. Zhang, X.D. Zhu, H.C. Sun, Y.Q. Xiong, P.Y. Zhuang, H.X. Xu, L.Q. Kong, L. Wang, W.Z. Wu, and Z.Y. Tang Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects Clin. Cancer Res. 16 13 2010 3420 3430